1. Home
  2. CALC vs FRSX Comparison

CALC vs FRSX Comparison

Compare CALC & FRSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CALC
  • FRSX
  • Stock Information
  • Founded
  • CALC 2011
  • FRSX N/A
  • Country
  • CALC United States
  • FRSX Israel
  • Employees
  • CALC N/A
  • FRSX N/A
  • Industry
  • CALC Biotechnology: Pharmaceutical Preparations
  • FRSX Computer Software: Prepackaged Software
  • Sector
  • CALC Health Care
  • FRSX Technology
  • Exchange
  • CALC Nasdaq
  • FRSX Nasdaq
  • Market Cap
  • CALC 22.9M
  • FRSX 9.0M
  • IPO Year
  • CALC N/A
  • FRSX 2017
  • Fundamental
  • Price
  • CALC $2.13
  • FRSX $0.50
  • Analyst Decision
  • CALC Strong Buy
  • FRSX
  • Analyst Count
  • CALC 2
  • FRSX 0
  • Target Price
  • CALC $14.50
  • FRSX N/A
  • AVG Volume (30 Days)
  • CALC 38.7K
  • FRSX 480.7K
  • Earning Date
  • CALC 08-11-2025
  • FRSX 08-08-2025
  • Dividend Yield
  • CALC N/A
  • FRSX N/A
  • EPS Growth
  • CALC N/A
  • FRSX N/A
  • EPS
  • CALC N/A
  • FRSX N/A
  • Revenue
  • CALC N/A
  • FRSX $436,000.00
  • Revenue This Year
  • CALC N/A
  • FRSX N/A
  • Revenue Next Year
  • CALC N/A
  • FRSX N/A
  • P/E Ratio
  • CALC N/A
  • FRSX N/A
  • Revenue Growth
  • CALC N/A
  • FRSX N/A
  • 52 Week Low
  • CALC $1.42
  • FRSX $0.45
  • 52 Week High
  • CALC $5.97
  • FRSX $2.63
  • Technical
  • Relative Strength Index (RSI)
  • CALC 48.14
  • FRSX 45.18
  • Support Level
  • CALC $1.59
  • FRSX $0.45
  • Resistance Level
  • CALC $1.69
  • FRSX $0.54
  • Average True Range (ATR)
  • CALC 0.15
  • FRSX 0.05
  • MACD
  • CALC 0.01
  • FRSX 0.01
  • Stochastic Oscillator
  • CALC 46.51
  • FRSX 35.50

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.

About FRSX Foresight Autonomous Holdings Ltd.

Foresight Autonomous Holdings Ltd is a technology company engaged in the design, development and commercialization of vision systems for the automotive industry. The company develops both in-line-of-sight vision systems and beyond-line-of-sight cellular-based applications through its wholly-owned subsidiaries. Its systems are designed to improve driving safety by enabling accurate and reliable threat detection while ensuring the lowest rates of false alerts. Foresight is pursuing several markets and believes its modern systems will revolutionize automotive safety by providing an automotive-grade, cost-effective platform.

Share on Social Networks: